Kymera Therapeutics Inc. has described proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a signal transducer and activator of transcription 6 (STAT6)-targeting moiety.
Patents from Oncopia Therapeutics Inc. (dba SK Life Science Labs) describe proteolysis targeting chimeric (PROTACs) compounds reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.
A Bristol Myers Squibb Co. patent detailed new substituted phenyl oxooxazolyl piperidine dione molecular glue degraders acting as DNA-binding protein Ikaros (IKZF1), zinc finger protein Helios (IKZF2), Aiolos (IKZF3) and Eos (IKZF4) degradation inducers potentially useful for the treatment of cancer.
Genentech Inc. has disclosed molecular glue compounds with the ability to induce cyclin-dependent kinase 2 (CDK2)/protein cereblon (CRBN) interaction for CDK2 degradation reported to be useful for the treatment of cancer.
Researchers from Captor Therapeutics Inc. presented the preclinical characterization of CT-01, a first-in-class GSPT-1 targeted degrader under investigation for the treatment of hepatocellular carcinoma.
Targeted protein degradation (TPD) is an alternative to conventional protein inhibition that is gaining attention due to advantages such as ensuring complete elimination of the target protein, reduced off-target effects or the potential to target previously inaccessible or “undruggable” proteins. Proteolysis targeting chimeras (PROTACs) are agents used for TPD that have proven effective for degradation of histone deacetylase (HDAC), among other different proteins.
Photys Therapeutics Inc. has signed a license agreement with Hangzhou Polymed Biopharmaceuticals Inc. for HPB-143, a phase I-ready IRAK-4 degrader. IRAK-4 degradation offers potential to treat various autoimmune indications, including atopic dermatitis and hidradenitis suppurativa.
Right open reading frame kinase 2 (RIOK2) plays an essential role in ribosome assembly and cell growth, survival and stress responses. Research has linked RIOK2 to tumor progression and poor prognosis in several types of cancer such as breast, lung, prostate or hematological tumors.
Lycia Therapeutics Inc. has reported progress in its immunology pipeline that comprises lysosomal targeting chimera (LYTAC)-based protein degradation therapies. The company is advancing its two lead programs toward the clinic: LCA-0061, a Catalytac degrader that catalytically degrades IgE, and LCA-0321, a Lytac degrader designed to specifically bind and rapidly deplete anti-thyroid-stimulating hormone receptor (TSHR) autoantibodies.
Auron Therapeutics Inc. has received FDA clearance of its IND application for its oral KAT2A/B degrader AUTX-703 in hematological malignancies. A phase I proof-of-concept trial in acute myeloid leukemia (AML) will open enrollment this quarter, supported by a recently completed $27 million series B financing.
RSS
